Catalyst Pharmaceutical Partners, Inc. Reports Successful Completion Of Type B Breakthrough Therapy Meeting With FDA On Firdapse Tablets Development Program
Published: Jan 06, 2014
CORAL GABLES, Fla., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, today announced the successful completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) about Firdapse™ tablets (Amifampridine), its lead product being evaluated for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS).
Help employers find you! Check out all the jobs and post your resume.